Cullinan Therapeutics, Inc. Common Stock (CGEM) is a publicly traded Healthcare sector company. As of September 14, 2026, CGEM trades at $21.53 with a market cap of $1.33B and a P/E ratio of 0.00. CGEM moved -1.95% today. Year to date, CGEM is +107.56%; over the trailing twelve months it is +211.03%. Its 52-week range spans $5.68 to $23.19. Analyst consensus is strong buy with an average price target of $34.11. Rallies surfaces CGEM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks CGEM insider trades, Form 4 activity, executive purchases, executive sales, shares, prices, and transaction dates when available.
| Metric | Value |
|---|---|
| Price | $21.53 |
| Market Cap | $1.33B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $23.19 |
| 52-Week Low | $5.68 |
| Volume | 944.10K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-219.88M |
| Gross Margin | 0.00% |
10 analysts cover CGEM: 0 strong buy, 10 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $34.11.